


PRODUCT: Zosuquidar trihydrochloride

ALTERNATE NAME: (αR)-4-[(1 α ,6 α ,10 β)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]- α -[(5-quinolinylloxy)methyl]-1-piperazineethanol trihydrochloride; LY335979

CATALOG #: 9488-5, 25

AMOUNT: 5 mg, 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₃₂H₃₁F₂N₃O₂·3HCl

MOLECULAR WEIGHT: 636.99

CAS NUMBER: 167465-36-3

APPEARANCE: White solid

SOLUBILITY: DMSO (>25 mg/ml)

PURITY: ≥98% by HPLC

STORAGE: Store at -20°C. Protect from air and moisture

DESCRIPTION: Zosuquidar is a potent P-glycoprotein (P-gp) inhibitor (K_d = 79 nM). Zosuquidar binds with high affinity to P-glycoprotein and inhibits P-glycoprotein-mediated multidrug resistance (MDR). Restores doxorubicin (Cat. No. 1527) sensitivity in P-gp-expressing multidrug (MDR) resistant cancer cell lines.

REFERENCES: Cripe, L.D., *et al.* (2010). *Blood* **116**, 4077-4085.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

Elacridar (Cat. No. 2792-5, 25)

MK-571 (Cat. No. 2691-5, 25)

MK-571, sodium salt (Cat. No. 2692-5, 25)

NSC-23925 (Cat. No. 2686-5, 25)

Tariquidar (Cat. No. 2853-10, 50)

USAGE: **FOR RESEARCH CH USE ONLY! Not to be used in humans**